- Home
- BTMD vs MCRB Comparison
BTMD vs MCRB Comparison
Compare BTMD & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- MCRB
- Stock Information
- Founded
- BTMD 2012
- MCRB 2010
- Country
- BTMD United States
- MCRB United States
- Employees
- BTMD N/A
- MCRB N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- MCRB Health Care
- Exchange
- BTMD Nasdaq
- MCRB Nasdaq
- Market Cap
- BTMD 127.8M
- MCRB 125.7M
- IPO Year
- BTMD N/A
- MCRB 2015
- Fundamental
- Price
- BTMD $3.04
- MCRB $15.19
- Analyst Decision
- BTMD Buy
- MCRB Hold
- Analyst Count
- BTMD 2
- MCRB 4
- Target Price
- BTMD $6.00
- MCRB $73.67
- AVG Volume (30 Days)
- BTMD 127.2K
- MCRB 158.8K
- Earning Date
- BTMD 08-06-2025
- MCRB 08-06-2025
- Dividend Yield
- BTMD N/A
- MCRB N/A
- EPS Growth
- BTMD 1489.51
- MCRB N/A
- EPS
- BTMD 0.88
- MCRB 10.22
- Revenue
- BTMD $199,073,000.00
- MCRB N/A
- Revenue This Year
- BTMD $5.87
- MCRB N/A
- Revenue Next Year
- BTMD $8.59
- MCRB N/A
- P/E Ratio
- BTMD $3.32
- MCRB $1.50
- Revenue Growth
- BTMD 6.32
- MCRB N/A
- 52 Week Low
- BTMD $2.87
- MCRB $6.53
- 52 Week High
- BTMD $7.25
- MCRB $26.40
- Technical
- Relative Strength Index (RSI)
- BTMD 28.39
- MCRB 60.77
- Support Level
- BTMD $3.88
- MCRB $13.51
- Resistance Level
- BTMD $4.20
- MCRB $15.96
- Average True Range (ATR)
- BTMD 0.25
- MCRB 1.47
- MACD
- BTMD -0.15
- MCRB -0.03
- Stochastic Oscillator
- BTMD 0.57
- MCRB 82.88
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.